Paton B C
Adv Cardiol. 1976;17:176-88. doi: 10.1159/000398838.
Since the start of the era of exclusive use of valve replacement in 1960, the only valve that has received continuous use [since 1962] has been the aortic homograft. Results with this valve indicate about a 60- to 70-percent 10-year survival rate. The next most continuously used designs have been the Smeloff-Cutter and the 1200-1260 series Starr-Edwards ball valves. Both of these valves have survival rates after 8 years of about 70%, and are, therefore, comparable to the homografts. More recently started series of homografts valves, tissue valves and prosthetic valves of various types appear to confer a better chance of 10-year survival than older valves in older series. Not all the improvements in survival rates can be ascribed to changes in valve design. Better selection of patients, improved intraoperative myocardial protection and better postoperative care all contribute to what appears to be progressive improvement in surgical results.
自1960年开始进入单纯使用瓣膜置换的时代以来，（自1962年起）唯一持续使用的瓣膜是主动脉同种异体移植物。使用这种瓣膜的结果显示10年生存率约为60%至70%。接下来持续使用时间最长的设计是斯梅洛夫-卡特瓣膜和1200 - 1260系列斯塔尔-爱德华兹球瓣。这两种瓣膜8年后的生存率约为70%，因此与同种异体移植物相当。最近开始使用的各种类型的同种异体移植物瓣膜、组织瓣膜和人工瓣膜系列，似乎比旧系列中的旧瓣膜有更好的10年生存机会。并非所有生存率的提高都可归因于瓣膜设计的改变。更好地选择患者、改善术中心肌保护和更好的术后护理都有助于手术结果似乎在逐步改善。
